I do not see Dacogen revenues disappearing at all. Dacogen works and is a very good product. I just do not see the huge growth coming, that we once were led to believe would develope. AML and other indications maybe in the cards and failed vidaza. The Adopt trial has superior response rates and quicker acting dacogen. We also have S110 that could be just what the doctor ordered. The EU will be difficult area to get a foot in the door and like anything, growth is the key. Supg may just be happy earning 40-60M a year, till the pipeline sees a approval.